Abstract:Abstract Introduction: Bruton's tyrosine kinase (BTK) is a clinical validated target for B cell lymphoma and autoimmune diseases. However, acquired resistance, which is the result of BTK C481S mutation, has been observed in patients. So reversible BTK inhibitors are developed to overcome acquired resistance of covalent BTK inhibitors. In order to achieve adequate efficacy, reversible BTK inhibitors require much higher exposure which may lead to higher risk of adverse effect. Proteolysis-targeting chimera (PROTAC) is a novel drug discovery strategy and achieve sustained target degradation though a catalytic mechanism of action. Comparing with traditional small molecule inhibitor, PROTAC has shown great advantages in overcoming acquired resistance, since potent and sustained active site occupation is no longer required. Here, we have identified a novel BTK-PROTAC HZ-Q1070 based on our DaTProD® platform, which is set up to promote the druggability research of PROTAC. After a series of evaluations, HZ-Q1070 has been validated as a promising pre-clinical candidate for further clinical development. Results: 1. HZ-Q1070 can effectively degrade BTK in cancer cell lines with DC50 < 0.05 nM. In vitro cancer cell growth inhibition assay, it completely suppressed the cell proliferation of a panel of lymphoma cell lines with IC50 < 0.05 nM, such as Mino, OCI-ly10 and TMD8. 2. At the same time, HZ-Q1070 catalyzes the mutated BTK degradation (C481S/C481Y/C481F/T474M) and potently inhibits growth of BTK inhibitor-resistant tumor cell lines. 3. In proteomic analysis assay, HZ-Q1070 can selectively degrade BTK. 4. HZ-Q1070 has been engineered to avoid Aiolos and Ikaros degradation and therefore does not show IMiD activity. 5. Mechanistic investigation of indicates that HZ-Q1070 can function through the ubiquitin-proteasome system (UPS). 6. In the PK/PD experiments, HZ-Q1070 shows excellent pharmacokinetic properties and BTK degradation activity in vivo. 7. HZ-Q1070 demonstrates robust tumor growth inhibition in TMD8 and Mino xenograft mouse model. Doses as low as 3 mg/kg demonstrates a significant inhibitory effect. Conclusion: In summary, HZ-Q1070 is a potent and highly selective BTK degrader against both BTK-WT and multiple BTK inhibitors-resistant mutations. In vivo, HZ-Q1070 exhibits excellent pharmacokinetic properties, BTK degradation activity and robust tumor growth inhibition in TMD8 and Mino mouse xenograft tumor model. These findings support further clinical development of HZ-Q1070 for the treatment of B cell malignancies. Citation Format: Xingguo Liu, Yubo Zhou, Yizhe Wu, Xiaomin Luo, Jiangfeng Xie, Xinxin Jin, Jia Li, Xinglu Zhou. Discovery and preclinical study of novel BTK degrader HZ-Q1070 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3450.

Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2

Targeting Triple-Negative Breast Cancer by a Novel Proteolysis Targeting Chimera Degrader of Enhancer of Zeste Homolog 2

Abstract P05: Novel PROTAC-based EZH2 Degraders Effectively Target Lymphoid Malignancies by Depleting Enzyme-Independent Functions of EZH2

Design and Synthesis of EZH2-Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2

Discovery of dihydropyridinone derivative as a covalent EZH2 degrader

Design, synthesis and evaluation of EZH2-based PROTACs targeting PRC2 complex in lymphoma

Discovery of the First-in-class G9a/GLP PROTAC Degrader

Chemically induced degradation of PRC2 complex by EZH2-Targeted PROTACs via a Ubiquitin-Proteasome pathway

Design, Synthesis, and Evaluation of VHL-based EZH2 Degraders for Breast Cancer

Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies

Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel–Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7

Design, synthesis, and biological evaluation of Wee1 kinase degraders

Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas

Regulation of EZH2 protein stability: new mechanisms, roles in tumorigenesis, and roads to the clinic

Abstract 3450: Discovery and preclinical study of novel BTK degrader HZ-Q1070

Potent and Selective Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) Heterobifunctional Small-molecule Degraders

Potent and Selective Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) Heterobifunctional Small-molecule Degraders.

EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex

Discovery of a SHP2 Degrader with In Vivo Anti-Tumor Activity

Hijacking the MDM2 E3 Ligase with novel BRD4-Targeting PROTACs in Pancreatic Cancer Cells

Discovery of novel pyridone-benzamide derivatives possessing a 1-methyl-2-benzimidazolinone moiety as potent EZH2 inhibitors for the treatment of B-cell lymphomas